The Roadmap Special Edition Report on Dolutegravir Resources – Page 5 – I-MAK


I-MAK’s team has spent the last decade increasing transparency on patents, innovation, and access.

Secondary Patenting of Branded Pharmaceuticals: A Case Study of How Patents on Two HIV Drugs Could Be Extended for Decades

T Amin and AS Kesselheim Health Aff 2012 Oct;31(10):2286-94. doi: 10.1377/hlthaff.2012.0107. Abstract Pharmaceutical manufacturers rely on patents to protect their intellectual property and often seek to extend market exclusivity for their products to maximize their return on investment. One method is by obtaining patents on features other than the original active drug ingredient, including secondary…

Journal Articles 14 Oct 2012

Partner with us now to build
a more just and equitable
medicine system for all.